Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

To be considered for this study, you need to be at least 18 years old and have a confirmed diagnosis of certain advanced cancers: mesothelioma affecting the lung or abdomen, a specific type of ovarian cancer (serous ovarian adenocarcinoma), cholangiocarcinoma, or non-small cell lung cancer. Your cancer cells must also have a certain amount of the mesothelin protein detectable through a special test.

You would also need to have tried at least one standard cancer treatment before, unless you have cholangiocarcinoma and chose not to have initial treatments. However, you can't have had more than five previous lines of treatment. Your general health, including your heart and other organ functions, would need to be good enough to take part, and you'd need suitable veins for collecting your blood cells.

If you decide to take part, the first step involves reading and signing a consent form to make sure you fully understand what's involved. You would then undergo several tests to confirm your eligibility, including a detailed review of your cancer tissue. If you qualify, some of your blood would be collected in a process called 'leukapheresis' – similar to donating blood, but only white blood cells are collected – to create the gavo-cel treatment. You would then receive the gavo-cel treatment, potentially along with other approved cancer-fighting drugs like fludarabine, cyclophosphamide, Nivolumab, or Ipilimumab, as decided by the study doctors.

After treatment, you would have regular check-ups, assessments (like scans and blood tests) to see how you're responding to the treatment and to monitor for any side effects. The study involves multiple visits to the clinic, and the total duration of your participation, including follow-up, will be clearly explained to you by the study team. You'll be closely monitored throughout the study.